Aktis Oncology (NASDAQ:AKTS) Stock Passes Above 50 Day Moving Average – What’s Next?

Aktis Oncology (NASDAQ:AKTS) crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $19.13 and traded as high as $19.73. Aktis Oncology shares last traded at $19.46, with a volume of 137,186 shares.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on AKTS. Weiss Ratings downgraded Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research note on Tuesday. William Blair began coverage on Aktis Oncology in a research note on Wednesday, April 29th. They set an “outperform” rating for the company. Finally, HC Wainwright lifted their target price on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $32.50.

Aktis Oncology Price Performance

The business’s fifty day simple moving average is $19.22.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings data on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The business had revenue of $1.87 million during the quarter. As a group, equities research analysts predict that Aktis Oncology will post -1.62 EPS for the current year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.